Insider · CIK 0001738054
Patel Gautam
director
Files at SPB (Spectrum Brands Holdings, Inc.), AMRX (Amneal Pharmaceuticals, Inc.). First filing Jan 6, 2025, latest Mar 5, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $2.0M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 31Weak | sell 610b5-1 | AMRX Amneal Pharmaceuticals, Inc. | $712k | 80,000 | -4% | +14% from low · -5% from high | |
| 15Weak | sell10b5-1 | AMRX Amneal Pharmaceuticals, Inc. | $651k | 80,000 | -4% | +6% from low · -12% from high | |
| 13Weak | sell10b5-1 | AMRX Amneal Pharmaceuticals, Inc. | $501k | 62,590 | -3% | +5% from low · -13% from high | |
| 6Weak | sell10b5-1 | AMRX Amneal Pharmaceuticals, Inc. | $139k | 17,410 | -1% | +1% from low · -16% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -80,000 | $8.90 | $712k | 1,808,886 | Mar 5, 2025 |
| Feb 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -80,000 | $8.14 | $651k | 1,888,886 | Feb 5, 2025 |
| Jan 8, 2025 | AMRX Amneal Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -62,590 | $8.01 | $501k | 1,968,886 | Jan 10, 2025 |
| Jan 2, 2025 | AMRX Amneal Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -17,410 | $8.01 | $139k | 2,031,476 | Jan 6, 2025 |
| Nov 19, 2024 | SPB Spectrum Brands Holdings, Inc. | AGrant or award Common Stock | +2,770 | $90.26 | $250k | 17,539 | Nov 20, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.